公开(公告)号：US20220249614A1

公开(公告)日：2022-08-11

申请号：US17720555

申请日：2022-04-14

Applicant: NOVARTIS AG

Inventor： William CHUTKOW ,  John Richard Neville HADCOCK ,  Kurt Alex HELDWEIN ,  Aimee Richardson USERA

IPC: A61K38/19 ,  A61K47/54 ,  A61K47/60 ,  A61P1/16

Abstract: The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same.

公开(公告)号：US20190000923A1

公开(公告)日：2019-01-03

申请号：US16064054

申请日：2016-12-20

Applicant: NOVARTIS AG

Inventor： William CHUTKOW ,  John Richard Neville HADCOCK ,  Kurt Alex HELDWEIN ,  Aimee Richardson USERA

IPC: A61K38/19 ,  A61P1/16 ,  A61K47/54 ,  A61K47/60

Abstract: The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same.